Psoriatic arthritis
sheila RHEUMarampa
3 years 10 months ago
Promising results of Risankizumab for #psoriaticarthritis
🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo
🔸Well tolerated and showed no safety signals
@RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g
Olga Petryna DrPetryna
3 years 10 months ago
Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf
Dr. Rachel Tate uptoTate
3 years 10 months ago
RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy
Dr. Antoni Chan synovialjoints
3 years 10 months ago
New treatments in #psoriaticarthritis Deucravacitinib TYK2 inhibitor selectively mediates cytokine signaling, specific inflammatory pathways (eg, IL-23, IL-12, and Type I interferons) concomitant with clinical symptom improvement @RheumNow #ACR21 Abst#0490 https://t.co/7JZGa5R4eC
Richard Conway RichardPAConway
3 years 10 months ago
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Olga Petryna DrPetryna
3 years 10 months ago
Abst 0452 #ACR21 #acrbest @RheumNow TB-PET/CT in PsA helps differentiate from RA/OA &measure inflammatory burden. Main findings asymmetric synovitis,systemic enthesitis, DIP& extensor tendons inflammation& adjacent nail matrix inflammation, Sacroiliitis& diffuse spine enthesitis https://t.co/7nTSIbmKfE
Mrinalini Dey DrMiniDey
3 years 10 months ago
#Fatigue is common in pts w/ #PsA- what is the impact on short-term disability?
Study of ~1200 pts finds greater annual short-term disability in pts with PsA & fatigue than w/o fatigue. Impact on QoL, work & socioeconomic costs.
@RheumNow #ACR21 Abs#0239
https://t.co/9yNBOovm2L https://t.co/l4tn0TSld1
Mrinalini Dey DrMiniDey
3 years 10 months ago
Excited for the first full day of #ACR21, reporting for @RheumNow!
Esp looking forward to:
⭐Posters: #Epidemiology, #PublicHealth, #COVID19, #SpA, #RheumatoidArthritis, #PatientOutcomes
⭐Plenary session
⭐Scientific sessions covering #axSpA, #PsA and more
David Liew drdavidliew
3 years 10 months ago
PsA bDMARD use in Australia🇦🇺
(where once you qualify for a bDMARD in general, it's the physician's free choice)
1. cool Sankey diagram showing switches
2. given the chance, people switch in all directions & switch hard
(registry linked with insurance)
#ACR21 ABST0201 @RheumNow https://t.co/jcVPa8jXsR
The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021. Below is a listing of some of their best studies for you to review and look for in the meeting. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Bristol Myers Squibb
The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021. Below is a listing of some of their best studies for you to review and look for in the meeting. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Aurinia
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017. (Abstract #1783).
Poster Hall